Advertisement

Pediatric Nephrology

, Volume 20, Issue 1, pp 36–41 | Cite as

Platelet-derived growth factor and platelet profiles in childhood nephrotic syndrome

  • Anna M. WasilewskaEmail author
  • Walentyna M. Zoch-Zwierz
  • Barbara Tomaszewska
  • Anna Biernacka
Original Article

Abstract

The aim of the study was to investigate (1) whether there are any changes in release of platelet-derived growth factor AA (PDGF AA) in children with nephrotic syndrome without clinical thromboembolic symptoms 2; (2) whether serum PDGF AA correlates with the platelet count (PLT) and platelet indices; (3) whether prednisone therapy affects the serum PDGF AA and the PLT; (4) whether PDGF AA is a useful predictor of disease activity. The study involved two groups of children: 33 with nephrotic syndrome (I) who were evaluated twice (A during relapse and B after 2 weeks of prednisone treatment) and 34 healthy children (II). The serum concentration of PDGF was measured by ELISA. In group I/A the PLT ( P <0.01) and platelet distribution width ( P <0.05) were elevated, the mean platelet volume (MPV) ( P <0.05) was decreased and the plateletcrit ( P >0.05) was normal. In group I/B, the PLT was decreased and MPV increased. The concentration of PDGF AA was still increased and correlated negatively with the albumin concentration. Hence in children with nephrotic syndrome an increase in PLT, a decrease in MPV, and a higher concentration of PDGF were observed. Treatment of nephrotic syndrome with prednisone for 2 weeks is not sufficient to normalize platelet parameters. Further studies are necessary to confirm the role of PDGF AA in the hypercoagulation state in children with nephrotic syndrome.

Keywords

Platelet count Mean platelet volume Plateletcrit Platelet distribution width Platelet-derived growth factor Nephrotic syndrome 

References

  1. 1.
    Anand NK, Chand G, Talib VH, Chellani H, Pande J (1996) Hemostatic profile in nephrotic syndrome. Indian Pediatr 33:1005–1012PubMedGoogle Scholar
  2. 2.
    Schlegel N (1997) Thromboembolic risks and complications in nephrotic syndrome. Semin Thromb Hemost 23:271–280PubMedGoogle Scholar
  3. 3.
    Tkaczyk M, Baj Z (2002) Surface markers of platelet function in idiopathic nephrotic syndrome in children. Pediatr Nephrol 17:673–677CrossRefPubMedGoogle Scholar
  4. 4.
    Sirolli V, Ballone E, Garofalo D, Merciaro G, Settefrati N, Di Mascio R, Di Gregorio P, Bonomini M (2002) Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron 91:424–430CrossRefPubMedGoogle Scholar
  5. 5.
    Kiliś-Pstrusińska K, Medyńska A, Wikiera-Magott I, Zwolińska D (2001) Levels of selected soluble adhesion molecules in blood serum of children with chronic glomerulonephritis. Pol Merkuriusz Lek 10:247–249PubMedGoogle Scholar
  6. 6.
    Mannaioni PF, Di Bello MG, Masini E (1997) Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 46:4–18PubMedGoogle Scholar
  7. 7.
    Abdullah R (1988) Hemostatic abnormalities in nephrotic syndrome. Vet Clin North Am Small Anim Pract 18:105–113Google Scholar
  8. 8.
    Bancroft AJ, Abel EW, Mcleran M, Belch JJ (2000) Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter thrombocytometer. Platelets 11:379–387CrossRefPubMedGoogle Scholar
  9. 9.
    Kapsoritakis AN, Koukourakis MI, Sfirdaki A, Potamianas SG, Kontroubakis IE, Kouroumalis EA (2001) Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 96:776–781PubMedGoogle Scholar
  10. 10.
    Pathansali R, Smith N, Bath P (2001) Altered megakaryocyte-platelet haemostatic axis in hypercholesterolemia. Platelets 12:292–297CrossRefPubMedGoogle Scholar
  11. 11.
    Planken MG van der, Vertessen FJ, Vertommen J, Engelen W, Berneman ZN, De Leeuw I (2000) Platelet prothrombinase activity, a final pathway platelet procoagulant activity is overexpressed in type I diabetes: no relationship with mean platelet volume or background retinopathy. Clin Appl Thromb Hemost 6:65–68PubMedGoogle Scholar
  12. 12.
    Toplak H, Wascher TC (1994) Influence of weight reduction on platelet volume: different effects of a hypocaloric diet and a very low calorie diet. Eur J Clin Invest 24:778–780PubMedGoogle Scholar
  13. 13.
    Botchway AN, Flores NA, Sheridan DJ, Cohen H (2000) Storage pool defect in pooled buffy coat platelet concentrates within the shelf-life period. Clin Lab Haematol 22:21–28CrossRefGoogle Scholar
  14. 14.
    Zdrojewski Z, Raszeja-Specht A, Kustosz J, Skibowska A, Rutkowski B (1996) Evaluation of factors influencing platelet aggregation in patients with chronic glomerulonephritis (CGN). Przegl Lek 53:434–438PubMedGoogle Scholar
  15. 15.
    Naito T, Nitta K, Ozu H, Tsuchiya K, Matsugami K, Honda K (1997) Clinical assessment of the significance of platelet-derived growth factor in patients with immunoglobulin A nephropathy. J Lab Clin Med 130:63–68CrossRefPubMedGoogle Scholar
  16. 16.
    Ostman A, Heldin CH (2001) Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 80:1–38CrossRefPubMedGoogle Scholar
  17. 17.
    Abdud HE (1995) Role of platelet-derived growth factor in renal injury. Annu Rev Physiol 57:297–309CrossRefPubMedGoogle Scholar
  18. 18.
    Floege J, Johnson BJ (1995) Multiple roles for platelet-derived growth in renal disease. Miner Electrolyte Metab 21:271–282PubMedGoogle Scholar
  19. 19.
    Helolin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1300PubMedGoogle Scholar
  20. 20.
    Soma Y, Dvonch V, Grotendorst GR (1992) Platelet-derived growth factor AA homodimer is the predominant isoform in human platelets and acute human wound fluid. FASEB J 6:2996–3001PubMedGoogle Scholar
  21. 21.
    Alpers CE, Hudkins KL, Ferguson M, Johnson RJ, Rutledge JC (1995) Platelet-derived growth factor A-chain expression in developing and mature human kidney and in Wilms’ tumor. Kidney Int 48:146–154PubMedGoogle Scholar
  22. 22.
    Couser WG (1998) Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 13:1–15Google Scholar
  23. 23.
    Johnson RJ, Floege J, Couser WG, Aplers CE (1993) Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol 4:119–128PubMedGoogle Scholar
  24. 24.
    Naito T (1994) Study on platelet-derived growth factor (PDGF) and PDGF receptor expression in glomeruli and corticosteroid therapy in IgA nephropathy. Nippon Jinzo Gakkai Shi 36:1113–1122PubMedGoogle Scholar
  25. 25.
    Ostendorf T, Kunter U, Roeyen C van, Dooley S, Jaryic N, Ruckman EF (2002) The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 13:658–667PubMedGoogle Scholar
  26. 26.
    Cameron JS (1984) Platelets in glomerular disease. Annu Rev Med 35:175–180CrossRefPubMedGoogle Scholar
  27. 27.
    Zdrojewski Z, Raszeja–Specht A, Skibowska A, Owczarzak A, Rutkowski A (1997) Hypercoagulation in patients with nephrotic syndrome. Pol Merkuriusz Lek 2:201–204PubMedGoogle Scholar
  28. 28.
    Goubran F, Maklady F (1988) In vivo platelet activity and serum albumin concentration in nephrotic syndrome. Blut 57:15–17PubMedGoogle Scholar
  29. 29.
    Jackson CA, Greaves M, Patterson AG, Brown CB, Prestan FE (1983) Relation between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haematol 52:69–77Google Scholar
  30. 30.
    Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M (1995) Platelet size, fibrinogen and lipoprotein (a) in coronary heart disease. Coron Artery Dis 6:397–402PubMedGoogle Scholar
  31. 31.
    Kenet G, Lubetsky A, Shenkman B, Tamarin J, Dardik R, Rechavi G (1998) Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 101:255–259CrossRefPubMedGoogle Scholar
  32. 32.
    Tkaczyk M, Owczarek D, Puczko-Nogal B, Makosiej R, Rogowska–Kalisz A, Ptaśnik W (2000) Activation of coagulation cascade in children during an idiopathic nephrotic syndrome. Pol Merkuriusz Lek 8:226–227PubMedGoogle Scholar
  33. 33.
    Graff J, Klinkhardt U, Harder S, Wegert W, Lenz T, Scheuermann EH (2002) Immunosuppressive therapy in renal transplant patients. Clin Pharmacol Ther 72:411–428CrossRefPubMedGoogle Scholar
  34. 34.
    Gesulado L, Di Paolo S, Milani S, Pinzani M, Grappone C, Ranieri E (1994) Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J Clin Invest 94:50–58PubMedGoogle Scholar
  35. 35.
    Lamb DJ, Avades TY, Ferns GAA (2001) Endogenous neutralizing antibodies against platelet-derived growth factor-AA inhibit atherogenesis in the cholesterol-fed rabbit. Arterioscler Thromb Vasc Biol 21:997–1003PubMedGoogle Scholar
  36. 36.
    Takehara K, Igarashi A, Ishibashi Y (1990) Dypiridamole specifically decreases platelet-derived growth factor release from platelets. Thromb Res 12:73–79CrossRefGoogle Scholar
  37. 37.
    Vissinger H, Husted SE, Kristensen SD, Nielsen HK (1993) Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylosalicylic acid. Angiology 44:633–638PubMedGoogle Scholar
  38. 38.
    Ozdemir O, Sayinalp NM, Haznedaroglu J, Arik N, Ozcebe OJ, Dundar S (1997) Mean platelet volume, platelet count and platelet dimensional width during hemodialysis. Thromb Res 86:405–408CrossRefPubMedGoogle Scholar
  39. 39.
    Rigatto C, Rush D, Pery Y, Walker S, Bose R, Bolli P (1997) Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation. Transplant Proc 29:2591–2592CrossRefPubMedGoogle Scholar
  40. 40.
    Ostendorf T, Kunter U, Grone HJ, Bahlmann F, Kawachi H, Shmizu F (2001) Specific antagonism of PDGF prevents renal scaring in experimental glomerulonephritis. J Am Soc Nephrol 12:909–918PubMedGoogle Scholar
  41. 41.
    Stein-Oakley AN, Maguire JA, Dowling J, Perry G, Thomson NM (2000) Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. Kidney Int 51:195–204Google Scholar
  42. 42.
    Zoja C, Remuzzi G (1997) Role of platelets in progressive glomerular diseases. Pediatr Nephrol 9:495–502Google Scholar
  43. 43.
    Kurogi Y (2003) Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 23:15–31CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2004

Authors and Affiliations

  • Anna M. Wasilewska
    • 1
    Email author
  • Walentyna M. Zoch-Zwierz
    • 1
  • Barbara Tomaszewska
    • 1
  • Anna Biernacka
    • 1
  1. 1.1st Department of PediatricsMedical University in BiałystokPoland

Personalised recommendations